MUC16 and cancer: Notably, the frequency of mutations in several key cancer-related genes was lower in the high-risk group compared to the low-risk group (TTN: 49% vs. 54%; TP53: 42% vs. 51%; MUC16: 26% vs. 36%; LRP1B: 26% vs. 30%) (Figure 9A, 9B).